A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.
Berlin J, Keedy V, Janne P, Yee L, Rizvi N, Jin X, Copigneaux C, Hettmann T, Beaupre D, LoRusso P. A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2011, 29: 3026-3026. DOI: 10.1200/jco.2011.29.15_suppl.3026.Peer-Reviewed Original Research